AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tumour ablations
Number of subjects: 34000
Study 33582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tumour resections
Number of subjects: 34000
Study 33582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive procedures
Number of subjects: 34000
Study 33582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thermal ablation
Number of subjects: 34000
Study 33582418 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of mirogabalin
Number of subjects: 0
Study 33582418 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of pregabalin
Number of subjects: 0
Study 33582418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33582955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 33582955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 33583058 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) plus social skills training
Number of subjects: 67
Study 33583058 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus social skills training
Number of subjects: 67
Study 33583206 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study 33583404 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity/participation goals
Number of subjects: 2591
Study 33583404 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-classifiable goals
Number of subjects: 2591
Study 33583408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 51
Study 33583408 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study 33583610 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitions Clinic Network (TCN) intervention
Number of subjects: 800
Study 33583610 — intervention group
Group type: COMPARATOR
Intervention: Referral to standard primary care
Number of subjects: 800
Study 33583755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 6217
Study 33583755 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-AF patients)
Number of subjects: 6217
Study 33584209 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Epidural Stimulation
Number of subjects: 0
Study 33584209 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33584491 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Balloon
Number of subjects: 0
Study 33584491 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stent
Number of subjects: 0
Study 33584535 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-derived biomarker cT1
Number of subjects: 264
Study 33584535 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-derived biomarker PDFF
Number of subjects: 264
Study 33585031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg intravenously or 162 mg subcutaneously
Number of subjects: 93
Study 33585031 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (CS) methylprednisolone 80 mg/day
Number of subjects: 93
Study 33585031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 33585179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 3748
Study 33585179 — intervention group
Group type: COMPARATOR
Intervention: Benign subjects with benign thyroid nodules
Number of subjects: 3748
Study 33585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance Learning Intervention
Number of subjects: 0
Study 33585394 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 33585418 — intervention group
Group type: EXPERIMENTAL
Intervention: Interjoint coordination measures post-stroke
Number of subjects: 0
Study 33585500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 4000
Study 33585503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Soluble Receptor for Advanced Glycation End Products
Number of subjects: 0
Study 33585521 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33585533 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 0
Study 33585533 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33585799 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion; 1 unit (68.2% of patients), 2 units (27.3% of patients), 3 units (4.5% of patients)
Number of subjects: 22
Study 33585799 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion
Number of subjects: 22
Study 33585999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10-25 mg bid) in combination with weekly paclitaxel (80 mg/m)
Number of subjects: 19
Study 33586138 — intervention group
Group type: COMPARATOR
Intervention: Aldosterone antagonists (spironolactone or eplerenone)
Number of subjects: 1446
Study 33586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB-UVB) treatment for 36 sessions
Number of subjects: 20
Study 33586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB-UVB) treatment
Number of subjects: 20
Study 33586174 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 20
Study 33586581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 200 mg/m²
Number of subjects: 34
Study 33586590 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6870810 (BET inhibitor)
Number of subjects: 32
Study 33586674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sema3G supplementation
Number of subjects: 0
Study 33586674 — intervention group
Group type: COMPARATOR
Intervention: Endothelial-specific Sema3G knockout
Number of subjects: 0
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus in collagen-elastin matrices
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus on dermal samples
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 2 min on human dermal samples
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated daily CAP treatments for 2 min on dermal samples
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated CAP treatment for 2 min on ex vivo human burn wound models
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 3× 20" on intact skin of volunteers
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment on intact skin of 15 volunteers contaminated with Pseudomonas aeruginosa
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering the plasma power during CAP treatment
Number of subjects: 25
Study 33587156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment
Number of subjects: 25
Study 33587350 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 33587350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib + Simvastatin
Number of subjects: 0
Study 33587435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based DAA therapy + Ribavirin (RBV)
Number of subjects: 29
Study 33587435 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-based DAA therapy
Number of subjects: 29
Study 33587499 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 181
Study 33587504 — intervention group
Group type: EXPERIMENTAL
Intervention: High HCV knowledge
Number of subjects: 151
Study 33587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with HCV for a decade
Number of subjects: 151
Study 33587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 151
Study 33587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HIV knowledge
Number of subjects: 151
Study 33587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HCV knowledge
Number of subjects: 151
Study 33587508 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV
Number of subjects: 1450
Study 33588101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed at inclusion
Number of subjects: 259
Study 33588101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed at 1-month follow-up
Number of subjects: 259
Study 33588101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed at 2-month follow-up
Number of subjects: 259
Study 33588101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) with liver stiffness less than 10 kPa
Number of subjects: 259
Study 33588101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) with liver stiffness greater than 25 kPa
Number of subjects: 259
Study 33588101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) for patients with initial liver stiffness of 10 to 25 kPa
Number of subjects: 259
Study 33588145 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 45
Study 33588149 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812 at 1300 mg three times a day (RP2D)
Number of subjects: 29
Study 33588149 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812 at 500 mg once a day to 2000 mg twice a day (escalation phase)
Number of subjects: 29
Study 33588149 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812
Number of subjects: 29
Study 33588912 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated detection of reverse triggering using airway pressure (Paw) and flow waveforms
Number of subjects: 20
Study 33588912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse triggering (RT)
Number of subjects: 20
Study 33588922 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 through 6, and every 4 weeks thereafter until progression or unacceptable toxicity; all cycles were 28 days.
Number of subjects: 32
Study 33588922 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously
Number of subjects: 32
Study 33588925 — intervention group
Group type: EXPERIMENTAL
Intervention: cDPP3 levels upon admission and 24 hours later
Number of subjects: 585
Study 33588925 — intervention group
Group type: EXPERIMENTAL
Intervention: cDPP3 levels upon admission
Number of subjects: 585
Study 33588925 — intervention group
Group type: EXPERIMENTAL
Intervention: cDPP3 levels > 40.4 ng/mL upon admission
Number of subjects: 585
Study 33588925 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently elevated cDPP3 at 24 hours
Number of subjects: 585
Study 33588932 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivered meal service
Number of subjects: 20
Study 33588932 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 33588948 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and high-intensity interval training (RT-HIIT)
Number of subjects: 88
Study 33588948 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and high-intensity interval training (AT-HIIT)
Number of subjects: 88
Study 33588948 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 88
Study 33589404 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio
Number of subjects: 454
Study 33589404 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher insulin concentration
Number of subjects: 454
Study 33589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0
Study 33589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 0
Study 33589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartesinin-piperaquine
Number of subjects: 0
Study 33589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous deployment of three ACTs
Number of subjects: 0
Study 33589520 — intervention group
Group type: EXPERIMENTAL
Intervention: αPD-1-mesoCAR-T cells
Number of subjects: 1
Study 33589520 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 1
Study 33589520 — intervention group
Group type: EXPERIMENTAL
Intervention: αPD-1-mesoCAR-T cells combined with apatinib
Number of subjects: 1
Study 33589539 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight (BMI 18.5-24.9 kg/m²)
Number of subjects: 25384
Study 33589539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight individuals
Number of subjects: 25384
Study 33589539 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight individuals
Number of subjects: 25384
Study 33589538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm motor therapy
Number of subjects: 77
Study 33589714 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain program (24-week, bi-weekly) including dual-task exercises, cognitive training, and mobile application-based nutritional guidance
Number of subjects: 0
Study 33589714 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33589714 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain program
Number of subjects: 0
Study 33590273 — intervention group
Group type: EXPERIMENTAL
Intervention: bolus injection of LAT-1 targeting PET tracer
Number of subjects: 6
Study 33590300 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide average African ancestry proportions
Number of subjects: 0
Study 33590300 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide average European ancestry proportions
Number of subjects: 0
Study 33590300 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide average Amerindigenous ancestry proportions
Number of subjects: 0
Study 33590300 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide average East Asian ancestry proportions
Number of subjects: 0
Study 33590349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 108
Study 33590349 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (EA)
Number of subjects: 108
Study 33590355 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic high-intensity vagus nerve stimulation (≥ 2.0 mA)
Number of subjects: 21
Study 33590674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic diet intervention for 6 months
Number of subjects: 28
Study 33590771 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9, LDLR and MPO measurements
Number of subjects: 0
Study 33590821 — intervention group
Group type: EXPERIMENTAL
Intervention: Withings Sleep Analyzers
Number of subjects: 118
Study 33590989 — intervention group
Group type: EXPERIMENTAL
Intervention: New minimally invasive bronchoscopic approaches and techniques for lung cancer and chronic lung diseases
Number of subjects: 0
Study 33590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation platforms for diagnosing and treating peripheral pulmonary nodules
Number of subjects: 0
Study 33590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound for diagnosis of mediastinal and hilar adenopathy
Number of subjects: 0
Study 33590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryobiopsy for diagnosis of diffuse lung diseases
Number of subjects: 0
Study 33590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible and rigid bronchoscopy for managing benign and malignant central airway obstruction
Number of subjects: 0
Study 33590994 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel exercise at 0.075 kg·m2 moment of inertia
Number of subjects: 19
Study 33590994 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel exercise
Number of subjects: 19
Study 33590994 — intervention group
Group type: COMPARATOR
Intervention: Aerobic fitness
Number of subjects: 19
Study 33590994 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 19
Study 33590994 — intervention group
Group type: COMPARATOR
Intervention: Max oxygen uptake
Number of subjects: 19
Study 33590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment alone
Number of subjects: 836
Study 33590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump
Number of subjects: 836
Study 33590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 836
Study 33590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive Inotropic Score quartiles
Number of subjects: 836
Study 33590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive Inotropic Score as a continuous value
Number of subjects: 836
Study 33591016 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced mean cerebral tissue oxygen saturation during the first 12 hours of monitoring
Number of subjects: 0
Study 33591016 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of cerebral tissue oxygen saturation desaturation
Number of subjects: 0
Study 33591017 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest normalized d-dimer level (≥ 8× the upper limit of normal)
Number of subjects: 3418
Study 33591041 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK surgery
Number of subjects: 50
Study 33591143 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine with 20 μg of fentanyl
Number of subjects: 0
Study 33591212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress testing during catheterization
Number of subjects: 21
Study 33591212 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-order model
Number of subjects: 21
Study 33591291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions administered by a comfort coach
Number of subjects: 154
Study 33591291 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 33591402 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treatment for pediatric renal tumors (e.g., bilateral Wilms tumor)
Number of subjects: 0
Study 33591402 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted and immune therapies
Number of subjects: 0
Study 33591402 — intervention group
Group type: EXPERIMENTAL
Intervention: Future trials
Number of subjects: 0
Study 33591468 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg oral daily) plus trastuzumab (6 mg/kg intravenous every 21 days)
Number of subjects: 103
Study 33591468 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus trastuzumab
Number of subjects: 103
Study 33591891 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema progression at CT
Number of subjects: 0
Study 33592103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin for 3 months
Number of subjects: 80
Study 33592103 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 80
Study 33592291 — intervention group
Group type: EXPERIMENTAL
Intervention: TA Treo device
Number of subjects: 46
Study 33592838 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion applied to the Heart meridian
Number of subjects: 120
Study 33592838 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion applied to the Lung meridian
Number of subjects: 120
Study 33592838 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 120
Study 33592838 — intervention group
Group type: COMPARATOR
Intervention: COPD group (no intervention)
Number of subjects: 120
Study 33592888 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-positive patients undergoing emergency digestive surgery
Number of subjects: 0
Study 33592888 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-negative patients undergoing emergency digestive surgery
Number of subjects: 0
Study 33592888 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (patients from March to June 2019)
Number of subjects: 0
Study 33593135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual tacrolimus 0.04 mg/kg/dose twice daily
Number of subjects: 10
Study 33593135 — intervention group
Group type: COMPARATOR
Intervention: Oral tacrolimus (after sublingual administration)
Number of subjects: 10
Study 33593311 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) and hypofractionated SBRT (5 fractions, total dose of 30 Gy with simultaneous integrated boost of 50 Gy on tumor-vessel interface) followed by IORT (10 Gy)
Number of subjects: 100
Study 33593430 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660 (one or two doses)
Number of subjects: 29
Study 33593448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus monotherapy (every 2 months)
Number of subjects: 40
Study 33593448 — intervention group
Group type: COMPARATOR
Intervention: Anti-vascular endothelial growth factor (VEGF) (monthly)
Number of subjects: 40
Study 33593448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus monotherapy
Number of subjects: 40
Study 33593448 — intervention group
Group type: COMPARATOR
Intervention: Anti-vascular endothelial growth factor (VEGF)
Number of subjects: 40
Study 33593763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics, including demographics, pathology, treatment and prognosis of patients with GBC in China
Number of subjects: 6000
Study 33593763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to clinical guidelines of GBC
Number of subjects: 6000
Study 33593763 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of clinical practice for diagnosing and treating GBC
Number of subjects: 6000
Study 33593799 — intervention group
Group type: EXPERIMENTAL
Intervention: Penumbra SMART Coil System
Number of subjects: 851
Study 33593867 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) treatment
Number of subjects: 25